Floatz logo

Blinatumomab

Measurable Residual Disease (MRD)

Hospital Universitario Dr. Jose E. Gonzalezmonoclonal_antibodyPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

3 Active assets in the Measurable Residual Disease (MRD) cohort.

Asset / SponsorPhaseRating
Venetoclax
Nanfang Hospital, Southern Medical University
Phase 2/3B
Sorafenib
Nanfang Hospital, Southern Medical University
Phase 2/3B
DEXAMETHASONE
Hospital Universitario Dr. Jose E. Gonzalez
Phase 2CCC

Same molecule, other indications

Blinatumomab is also rated in:

precursor B-cell acute lymphoblastic leukemiaDormant
BBB
Indicative ·
72 / 100
View asset →
B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2)Dormant
BBB
Indicative ·
72 / 100
View asset →
Precursor B-Cell Acute Lymphoblastic LeukemiaDormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →